The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study

Schizophrenia Research
J F CastelãoS L Heylen

Abstract

After a wash-out period of 1 week, 20 patients suffering from schizophrenia were treated for 4 weeks in an open dose-finding study with a new serotonin-dopamine antagonist risperidone. All patients completed the trial. The mean daily dose of risperidone was 4.6 mg (range 2-10 mg) at completion. Risperiodone had a rapid onset of action: a highly significant decrease of the total BPRS score (Brief Psychiatric Rating Scale) was already noticed at the end of the second week. This decrease was found in all BPRS factors after 4 weeks. In spite of the withdrawal of antiparkinson medication at selection, a clear decrease of EPS (extrapyramidal symptoms), assessed on the Simpson and Angus Scale, was observed. The Global Therapeutic Impression agreed to the BPRS scores, showing a highly significant improvement after 2 weeks of treatment. Risperidone was very well tolerated, only mild side effects were reported. Vital signs, electrocardiographic parameters and laboratory values remained normal during the trial. This study indicates that risperidone can be an effective and well-tolerated alternative in the treatment of chronic schizophrenia, combining an antipsychotic activity, a beneficial effect on anergia and anxiety depression and a lo...Continue Reading

References

Jan 1, 1976·Schizophrenia Bulletin·H Y Meltzer, S M Stahl
Jan 1, 1985·Schizophrenia Bulletin·T J Crow
Jul 16, 1986·Brain Research·C IdzikowskiR Glennard
Jul 1, 1986·Comprehensive Psychiatry·J P LindenmayerC Friedman
Jul 1, 1974·Archives of General Psychiatry·T Van Putten
Nov 1, 1982·Electroencephalography and Clinical Neurophysiology·I OswaldR Spiegel
Jun 1, 1981·Archives of General Psychiatry·L E DeLisiR J Wyatt
Jun 1, 1981·Archives of General Psychiatry·D X FreedmanJ W Crayton
Oct 1, 1980·The British Journal of Psychiatry : the Journal of Mental Science·A V Mackay

❮ Previous
Next ❯

Citations

Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E MohrP P De Deyn
Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·H J MöllerH Schubert
Mar 1, 1994·Pharmacology, Biochemistry, and Behavior·T SumiyoshiK Yokogawa
May 1, 1995·Pharmacology & Therapeutics·P R Saxena
Jan 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·K HeinrichH Hruschka
Jul 5, 2001·European Journal of Pharmacology·N KawashimaS Okuyama
Nov 10, 1998·European Journal of Pharmacology·I Ninan, S K Kulkarni
Oct 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·H Quintana, M Keshavan
Dec 1, 1993·Annals of Emergency Medicine·K BrownE L Hamburg
Mar 16, 2001·Expert Opinion on Pharmacotherapy·R C Love, M W Nelson
Sep 1, 1995·Acta Neuropsychiatrica·J A den Boer
Jan 1, 2009·International Journal of Psychiatry in Clinical Practice·Reiji YoshimuraJun Nakamura
Feb 24, 2001·Journal of Psychopharmacology·D M Taylor, D Duncan-McConnell
Apr 15, 2005·Human Psychopharmacology·Reiji YoshimuraHisao Maeda
Oct 8, 1997·Journal of Clinical Psychopharmacology·M Brecher, W Geller
Sep 1, 1994·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S E PurdonB D Jones
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·H Y MeltzerR Ranjan
Feb 25, 2003·International Clinical Psychopharmacology·Reiji YoshimuraJun Nakamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here